Search results for "dopamine receptor"

showing 10 items of 125 documents

Interactions and Monitoring of Antipsychotic Drugs

2012

As a consequence of individualized antipsychotic pharmacotherapy, many patients need more than a single drug, since they do not respond sufficiently to monotherapy. Other patients suffer from comorbid diseases and therefore require additional drugs from other pharmacological classes. Drug combinations, however, can give rise to pharmacokinetic and/or pharmacodynamic drug–drug interactions. Evaluation of pharmacokinetic interactions with antipsychotic drugs must consider substrate, inhibitor, and inducer properties for the cytochrome P450 (CYP) isoenzymes of all combined drugs. For consideration of pharmacodynamic interactions, special attention must be given to effects on dopamine D2, hista…

Drugmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectPharmacologyPharmacotherapyPharmacokineticsExtrapyramidal symptomsTherapeutic drug monitoringPharmacodynamicsDopamine receptor D2Medicinemedicine.symptombusinessAntipsychoticmedia_common
researchProduct

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

2002

Abstract The current concept of dyskinesia is that pulsatile stimulation of D-1 or D-2 receptors by l -DOPA or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. We now investigate the ability of two mixed D-1/D-2 agonists, namely pergolide (long-acting) and apomorphine (short-acting), to induce dyskinesia in drug-naive MPTP-lesioned primates, compared to l -DOPA. Adult common marmosets ( Callithrix jacchus ) were lesioned with MPTP (2 mg/kg/day sc for 5 days) and subsequently treated with equieffective antiparkinsonian doses of l -DOPA, apomorphine, or pergolide for 28 days. l -DOPA, apomorphine, …

Dyskinesia Drug-Inducedmedicine.medical_specialtyParkinson's diseaseL-DOPApergolideMotor ActivityapomorphineSeverity of Illness IndexDopamine agonistAntiparkinson AgentsLevodopaParkinson’s disease.Disability Evaluationchemistry.chemical_compoundParkinsonian DisordersDevelopmental NeuroscienceDopamineInternal medicineAnimalsMedicineMPTPPergolidemarmosetBehavior AnimalReceptors Dopamine D2business.industryReceptors Dopamine D1MPTPCallithrixmedicine.diseasenervous system diseasesApomorphineDisease Models AnimaldyskinesiaEndocrinologyNeurologychemistryDyskinesia1-Methyl-4-phenyl-1236-tetrahydropyridineDopamine receptorDopamine AgonistsSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drugExperimental Neurology
researchProduct

Genetic polymorphism in dopamine receptor D4 is associated with early body condition in a large population of greater flamingos,Phoenicopterus roseus

2012

Body condition is an important determinant of fitness in many natural populations. However, as for many fitness traits, the underlying genes that regulate body condition remain elusive. The dopamine receptor D4 gene (DRD4) is a promising candidate as dopamine is known to play an important role in the regulation of food intake and the metabolism of both glucose and lipids in vertebrates. In this study, we take advantage of a large data set of greater flamingos, Phoenicopterus roseus, to test whether DRD4 polymorphism predicts early body condition (EBC) while controlling for whole-genome effects of inbreeding and outbreeding using microsatellite multilocus heterozygosity (MLH). We typed 670 o…

GeneticsCandidate geneOutbreeding depressionSingle-nucleotide polymorphismBiologyLoss of heterozygosityExonmental disordersGeneticsDopamine receptor D4biology.proteinInbreedingGeneEcology Evolution Behavior and SystematicsMolecular Ecology
researchProduct

Indole-substituted 2,4-diamino-5,8-dihydropyrido[2,3-d]pyrimidines from one-pot process and evaluation of their ability to bind dopamine receptors

2018

A series of novel 7-indole substituted 2,4-diamino-5,8-dihydropyrido[2,3-d]pyrimidine analogous to the 2,4-diaminopteridine core were synthesized by the three-component one-pot cyclocondensation between 2,4,6-triaminopyrimidine, 3-(2-cyanoacetyl)indole and aromatic aldehydes. The reactions, which exhibited good performance, proceeded in EtOH using indium (III) chloride as catalyst under microwave irradiation, in short reaction times. On the basis of certain structural similarity of these compounds with known ligands of the D2 dopamine receptors (D2DR), the study of these compounds as possible ligands of dopamine D2 and D1 receptors was carried out. Three of them showed moderate affinity to …

Indole testPYRIDOPYRIMIDINE010405 organic chemistryChemistryStereochemistryOrganic ChemistryCiencias QuímicasTHREE-COMPONENT SYNTHESIS010402 general chemistryBIND DOPAMINE01 natural sciencesBiochemistry0104 chemical sciencesQuímica OrgánicaD1 AND D2 RECEPTORSDopamine receptorDrug DiscoveryMOLECULAR MODELINGCIENCIAS NATURALES Y EXACTASTetrahedron
researchProduct

The multiple roles of dopamine receptor activation in the modulation of gastrointestinal motility and mucosal function

2022

Dopamine (DA) is a catecholamine regulatory molecule with potential role in physiology and physiopathology of the intestinal tract. Various cellular sources of DA have been indicated as enteric neurons, immune cells, intestinal flora and gastrointestinal epithelium. Moreover, DA is produced by nutritional tyrosine. All the five DA receptors, actually described, are present throughout the gut. Current knowledge of DA in this area is reviewed, focusing on gastrointestinal function in health and during inflammation. Research on animal models and humans are reported. A major obstacle to understanding the physiologic and/or pharmacological roles of enteric DA is represented by the multiplicity o…

InflammationGastrointestinal inflammationCellular and Molecular NeuroscienceCatecholaminesGastrointestinal motilityEndocrine and Autonomic SystemsDopamineHumansAnimalsGastrointestinal transportNeurology (clinical)Dopamine receptorsReceptors DopamineAutonomic Neuroscience
researchProduct

Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson's disease

2010

Oxidative stress is involved in the pathogenesis of various neurodegenerative disorders, conventional antioxidant strategies have yet been of limited success. We have employed transgenic Caenorhabditis elegans expressing DsRed2 in dopaminergic neurons and CFP pan-neuronally, to characterize in larval and adult animals the effects of rotenone and 1-methyl-4-phenyl-pyridinium (MPP(+)) on the dopaminergic system. Investigating the antioxidant phenothiazine and different derived antipsychotic drugs, it was found that free phenothiazine exerted strong neuroprotection at the cellular level and resulted in a better performance in behavioral assays, whereas apomorphine and other dopamine agonists o…

InsecticidesApomorphineChlorpromazineDopamineBiologyPharmacologyNeuroprotectionlcsh:RC321-571Animals Genetically Modifiedchemistry.chemical_compoundAntipsychotic drugParkinsonian DisordersDopaminePhenothiazinesRotenonemedicineAnimalsHumansChlorpromazineCaenorhabditis eleganslcsh:Neurosciences. Biological psychiatry. Neuropsychiatrychemistry.chemical_classificationNeuronsDopaminergic neuronModels GeneticNeurodegenerationDopaminergicRotenonemedicine.diseaseDisease Models AnimalNeuroprotective AgentsNeurologychemistryDopamine receptorNerve DegenerationAntioxidantTricyclicmedicine.drugAntipsychotic AgentsNeurobiology of Disease
researchProduct

Synthesis and characterization of biotinylated and photoactivatable neuroleptics. Novel bifunctional probes for dopamine receptors

1992

Abstract We have synthesized and characterized a series of novel derivatives of established antagonists of the neurotransmitter dopamine, i.e. butyrophenones, hexahydrocarbolines and phenothiazenes. All derivatives were biotinylated, some of them carried an additional (photoactivatable) azido group. In the case of butyrophenones, the structural modifications were introduced at the aliphatic keto group and/or the heterocyclic ring system, both modifications resulting in significant decreases in binding affinity to dopamine D 2 and dopamine D 1 receptor subtypes. Biotinylation of hexahydrocarbolines significantly increased their binding affinity to D 1 receptors, with the affinity for D 2 rec…

Magnetic Resonance SpectroscopySpectrophotometry InfraredPhotochemistryButyrophenoneStereochemistryBiotinIn Vitro TechniquesLigandsBinding CompetitiveReceptors DopamineStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDopaminemedicineAnimalsNeurotransmitterReceptor030304 developmental biologyPharmacology0303 health sciencesDopamine antagonistAffinity LabelsBenzazepineschemistryBiochemistrySpiperoneDopamine receptorBiotinylationCattleButyrophenones030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugEuropean Journal of Pharmacology: Molecular Pharmacology
researchProduct

Causal Link between n-3 Polyunsaturated Fatty Acid Deficiency and Motivation Deficits

2020

International audience; Reward-processing impairment is a common symptomatic dimension of several psychiatric disorders. However, whether the underlying pathological mechanisms are common is unknown. Herein, we asked if the decrease in the n-3 polyunsaturated fatty acid (PUFA) lipid species, consistently described in these pathologies, could underlie reward-processing deficits. We show that reduced n-3 PUFA biostatus in mice leads to selective motivational impairments. Electrophysiological recordings revealed increased collateral inhibition of dopamine D2 receptor-expressing medium spiny neurons (D2-MSNs) onto dopamine D1 receptor-expressing MSNs in the nucleus accumbens, a main brain regio…

Male0301 basic medicineN-3 PUFAPhysiology[SDV]Life Sciences [q-bio]DopamineMice TransgenicNucleus accumbensMedium spiny neuronMice03 medical and health sciences0302 clinical medicineDopamineDopamine receptor D2Fatty Acids Omega-3medicineAnimalsMolecular BiologyPathological030304 developmental biologyNeuronsMedium spiny neuronschemistry.chemical_classification[SDV.GEN]Life Sciences [q-bio]/Genetics0303 health sciencesMotivationReceptors Dopamine D2business.industry[SCCO.NEUR]Cognitive science/NeuroscienceCell BiologyMice Inbred C57BLElectrophysiology[SDV.GEN.GA]Life Sciences [q-bio]/Genetics/Animal geneticsElectrophysiology030104 developmental biologychemistryNucleus accumbensFemalePolyunsaturated fatty acids[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Causal linkbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugPolyunsaturated fatty acidCell Metabolism
researchProduct

MAOA-VNTR polymorphism modulates context-dependent dopamine release and aggressive behavior in males

2016

A recent [F-18]FDOPA-PET study reports negative correlations between dopamine synthesis rates and aggressive behavior. Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli. We selected from a genetic prescreening sample, strictly case-matched groups of 2 x 12 healthy male subjects with VNTRs predictive of high (MAOA-High) and low (MAOA-Low) MAOA expression. Subjects underwent pairs of PET sessions (dopamine D-2/3 ligand [F-18]DM…

Male0301 basic medicinemedicine.medical_specialtyGenotypeCognitive NeuroscienceDopamineContext (language use)Polymorphism Single NucleotideDevelopmental psychologyYoung Adult03 medical and health sciences0302 clinical medicineDopaminePolymorphism (computer science)Dopamine receptor D2Internal medicineImage Processing Computer-AssistedmedicineHumansMAOAYoung adultMonoamine OxidasebiologyAggressionDopaminergicBrainDMFPAggression030104 developmental biologyEndocrinologyPETNeurologyPositron-Emission Tomographybiology.proteinmedicine.symptomMonoamine oxidase APsychology030217 neurology & neurosurgerymedicine.drug
researchProduct

Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant

1998

Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions and to block the formation of conditioned place preferences; these effects are reversed by chronic treatment with tricyclic or atypical antidepressant drugs. The present study was designed to evaluate the antidepressant-like activity in this model of flibaserin (BIMT-17), a novel serotonergic agent with 5-HT1A receptor agonist and 5-HT2 receptor antagonist properties. Two experiments were conducted, using rats (experiment 1) and mice (experiment 2). In experiment 1, decreases in sucrose intake were seen in rats exposed to chronic mild stress, but the effect was unr…

MaleAgonistSucrosemedicine.medical_specialtyQuinpirolemedicine.drug_classMotor ActivityMiceSerotonin AgentsQuinpiroleDopamine receptor D3Dopamine receptor D2Internal medicineSalicylamidesmedicineAnimalsRats WistarPharmacologyRacloprideFluoxetinebusiness.industryBody WeightFeeding BehaviorConditioned place preferenceRatsEndocrinologyRacloprideAntidepressive Agents Second-GenerationConditioning OperantDopamine AntagonistsFlibanserinBenzimidazolesbusinessStress Psychologicalmedicine.drugEuropean Journal of Pharmacology
researchProduct